Form 4: Crinetics Pharmaceuticals Executive James Hassard Executes Stock Option and Sells Shares

Crinetics Pharmaceuticals' Chief Commercial Officer, James Hassard, exercised stock options and sold 15,000 shares of common stock on June 21, 2024, according to a Form 4 filing.

Summary

• On June 21, 2024, James Hassard, Chief Commercial Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 15,000 shares of common stock at a price of $19.73 per share.
• Simultaneously, Hassard sold 15,000 shares of common stock in the open market at a volume-weighted average price of $44.66 per share, with prices ranging from $43.96 to $45.11.
• Following these transactions, Hassard directly owns 29,259 shares of Crinetics Pharmaceuticals' common stock and holds options for 145,000 shares.
• The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction by an executive under a pre-existing plan. The exercise of options and subsequent sale is neither overtly positive nor negative.

Future Outlook

The document does not contain specific forward-looking statements, but the executive's continued stock ownership and option holdings suggest a continued alignment with the company's future performance.

Industry Context

Executive stock transactions are common and closely monitored in the pharmaceutical industry. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are standard across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives.
• The use of Rule 10b5-1 trading plans is a common practice to avoid insider trading concerns.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sale mitigates potential concerns.
• The executive's continued employment and option holdings suggest ongoing commitment to the company.

Key Dates